Detalhe da pesquisa
1.
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
J Am Acad Dermatol
; 75(6): 1162-1170.e3, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27692733
2.
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
BMC Dermatol
; 15: 8, 2015 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25951857
3.
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
J Drugs Dermatol
; 13(3): 252-6, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24595567